Dr Fyodor Urnov: The power and promise of ZFN-mediated genome editing

In News by


BioInsights talks to Dr Fyodor Urnov, Project Leader and Senior Scientist at Sangamo BioSciences, Inc., USA

Dr Fyodor Urnov, Sangamo BioSciences

Fyodor Urnov, PhD, is Project Leader and Senior Scientist at Sangamo BioSciences, Inc. where he co-developed human genome editing with engineered zinc finger nucleases (ZFNs). Dr Urnov previously led the company’s research and development efforts in deploying genome editing for crop trait engineering (in partnership with Dow Agrosciences) and in generation of engineered cell lines for manufacturing, improved generation of transgenic animals and as research reagents (in partnership with Sigma-Aldrich). In his current role as Project Leader for the Hemoglobinopathies, Dr Urnov heads Sangamo’s collaboration with Biogen to develop genome editing as a one time, lasting treatment for beta-thalassemia and sickle cell disease. Dr Urnov is also an associate adjunct professor in the department of Molecular and Cell Biology at the University of California, Berkeley. Dr Urnov received his PhD from Brown University and holds a BSc in Biology from Moscow State University. He is an author on more than 60 scientific publications and an inventor on more than 90 issued and pending US patents related to ZFN technology.

Read the published interview here